Company Overview of Bio-Cancer Treatment International Ltd.
Bio-Cancer Treatment International, Ltd. operates as a biotech company in Hong Kong. It develops BCT-100, an anti-cancer drug candidate, which is a recombinant human enzyme for the treatment of cancers that are dependent on arginine for growth. The company also develops chemical synthetic technology to produce polyethylene glycol; and mSPA-PEG, a bio-polymer used in the production of BCT-100 and other protein therapeutics. It has strategic partnerships with Morningside Asia and Kinexum. The company was founded in 2001 and is based in Shatin, Hong Kong.
Hong Kong Science Park
2 Science Park West Avenue
Room 511-513, 5/F
Founded in 2001
852 2521 1566
852 2521 1560
Key Executives for Bio-Cancer Treatment International Ltd.
Similar Private Companies By Industry
|Antiviral Technologies, Inc.||Asia|
|Bio-Cancer Treatment International Ltd.||Asia|
|Bio-Works Company Limited||Asia|
|China Gene, Ltd. (Hong Kong)||Asia|
|DiagCor Bioscience Incorporation Limited||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Bio-Cancer Treatment International Ltd., please visit www.bio-cancer.org. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.